Qatar’s First Humanitarian Org Celebrates 40 Years

Last March 20, Qatar Red Crescent Society or QRCS held a grand celebration of its 40-year anniversary at the Katara Cultural Village in Doha. Attended by the country’s government officials, business leaders, senior officers and volunteers, and other representatives, it was an important event in the field of development and humanitarian advocacy. But it marked even more important achievements.

Established on March 20, 1978, QRCS “boasts of a track record of achievements, lessons learnt and milestones”, it has said in a statement. “These successes have shaped the arena of charitable and social work in Qatar, and enriched the country’s bright image as a major humanitarian player around the world.”

Committed to its slogan “Saving Lives and Preserving Dignity,” the QRCS—as a member of the International Federation of the Red Cross and Red Crescent Societies and the International Committee of the Red Cross (ICRC)—has helped develop zones afflicted by disasters, conflict, and poverty.

“Being Qatar’s first humanitarian organisation, QRCS became a pioneer in its vision, principles and efforts. Now, it serves as an auxiliary to Qatar in its humanitarian policies both locally and internationally. Also, it has become a role model for many NGOs and humanitarian service providers, which follow its strategies and operations,” the statement adds.

The day’s highlights include a special ceremony to honor the organization’s chief contributors and volunteers, the opening to a public exhibit of QRCS’s timeline and history at the Katara Corniche, a showcase and invitation for volunteering opportunities, and even kid-friendly activities.

However, humanitarian advocacy is not only enacted on the organization level, but some powerful individuals constantly do their share, exemplified by other recent milestones in philantropy such as charity auctions for the homeless and benefit concerts for diverse causes. Perhaps even in our smallness, we could wonder about the small ways we could contribute to the giant mission of relieving the suffering of others.

--> Help make the world a better place by sharing this story with your friends:

Pediatric Cancer Drug Displays 93% Success Rate

Breakthroughs in cancer research such as gene-altering treatments and the discovery of nanomachines have made waves in the past few years, persistently leading humanity through not-so-tiny victory after not-so-tiny victory in a battle between human and disease that has spanned decades. Just this month, a drug specifically targeting a fused gene found in several cancer types resulted in a 93% response rate among children.

“In some cancers, a part of the TRK [tropomyosin receptor kinase] gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it’s not supposed to be and that causes the cells to grow uncontrollably. What’s unique about the drug is it is very selective; it only blocks TRK receptors,” said lead author Dr. Ted Laetsch, Assistant Professor of Pediatrics.

Most drugs that are already known and used to cure cancer usually target a particular location or organ in the body. According to the researchers at UT Southwestern’s Simmons Cancer Center, Larotrectinib is the first cancer drug designated for people with TRK fusions, or the fusion of two genes in the cancer cell, regardless of whether their cancer is in the lung, colon, or other areas.

“…none of the patients with TRK fusions had to quit the study because of a drug-induced side effect. Equally important, the response was long-lasting for most patients.”

The TRK fusions tend to occur mostly in certain types of pediatric cancer. This implies that, despite also being 75% effective in adult cancers, Larotrectinib is a bigger breakthrough in pediatric cancer research. This is a hopeful and life-giving discovery for children, or the people most capable of giving us hope in our own lives.

--> Help make the world a better place by sharing this story with your friends: